Document is current
Any future updates will be listed below
-
Authors
Ibarra-Arellano, Miguel A. https://orcid.org/0000-0001-8411-4854
Caprio, Lindsay A. https://orcid.org/0000-0003-1370-8684
Hada, Aroj
Stotzem, Niklas
Cai, Luke L.
Shah, Shivem B. https://orcid.org/0000-0001-9439-6509
Walsh, Zachary H.
Melms, Johannes C. https://orcid.org/0000-0002-5410-6586
Wünneman, Florian
Bestak, Kresimir
Mansaray, Ibrahim
Izar, Benjamin https://orcid.org/0000-0003-2379-6702
Schapiro, Denis https://orcid.org/0000-0002-9391-5722
- License Information
-
More Information
Article History
Received: 24 May 2024
Accepted: 21 February 2025
First Online: 4 March 2025
Competing interests
: D.S. reports funding from Cellzome, a GSK company and received honorariums from Immunai, Noetik, Alpenglow and Lunaphore. B.I. is a consultant for or received honoraria from Volastra Therapeutics, Johnson & Johnson/Janssen, Novartis, Eisai, AstraZeneca and Merck, and has received research funding to Columbia University from Agenus, Alkermes, Arcus Biosciences, Checkmate Pharmaceuticals, Compugen, Immunocore, Regeneron, and Synthekine. All other authors declare no competing interests.
